Pfizer says antiviral COVID-19 pill effective against severe illness, omicron variant
Among those at high risk for severe illness from COVID-19 are the elderly, those with underlying medical conditions
The Facts Inside Our Reporter’s Notebook
Pfizer announced Tuesday that a final analysis of its experimental COVID-19 antiviral pill sharply reduced hospitalizations and deaths among people at high risk of severe illness from the virus.
The final study reinforces an earlier analysis from November, according to The Washington Post.
Pfizer’s Paxlovid pill cut hospitalizations and deaths by nearly 90% when taken within three or five days of the onset of symptoms, the company announced. Preliminary laboratory studies also suggest the pill is effective against COVID’S omicron variant, the Post also reports.
Among those at high risk for severe illness are the elderly and those with underlying medical conditions.
Pfizer and Merck each have antiviral medications under consideration by regulators, as health-care professionals, pharmaceutical companies and others hasten to learn how effective existing vaccination shots are against omicron, or whether new vaccines or booster shots are needed.
Just News, No Noise
- New twist in FBI raid: Trump had 'standing order' to declassify documents taken to residence
- Marjorie Taylor Greene files articles of impeachment against Merrick Garland
- Top Democrat Clyburn: $740 billion spending-tax bill will be issue in midterm elections
- Arizona’s U.S. Senate seat rated a toss-up by election forecasters
- Two Democratic lawmakers cast 10 proxy votes each on House floor in favor of $740B spending bill